Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS SC Actinic Keratosis Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    ACTINIC KERATOSIS - SCORE

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs step-therapy coverage for diclofenac sodium gel 3% for actinic keratosis under the South Carolina Medicare Advantage prescription drug program. Coverage requires a prior trial of either topical fluorouracil or topical imiquimod.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyACTINIC KERATOSIS - SCORE
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 202744d
    Next Review DateN/A
    Key ActionDocument a trial of either topical fluorouracil or topical imiquimod before requesting diclofenac sodium gel 3% coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1Product affected
    2Acceptable prerequisite therapies
    3%Diclofenac gel strength
    2Additional products affected
    New starts

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Zonisade step applies to

    Coverage Criteria

    Initial step therapy

    Diclofenac sodium gel 3% coverage requires the following step criterion.

    Prior topical therapy

    • Topical fluorouracil: Trial of topical fluorouracil
    • Topical imiquimod: Trial of topical imiquimod

    Farxiga initial therapy

    Farxiga coverage requires the following step:

    Required generic trial: Trial of generic dapagliflozin

    Zonisade initial therapy

    Zonisade coverage for new starts requires the following step:

    Required generic trial: Trial of generic zonisamide capsule

    Step applies to new starts only.

    Zonisade continuation therapy

    Continuation of prior therapy may be approved.

    Continuation: Member is continuing prior Zonisade therapy

    Continuation is permitted because the step requirement applies to new starts only.

    Provider Actions and Documentation

    Step Therapy

    Topical Prerequisite Therapy Required

    Before coverage of diclofenac sodium gel 3%, document a trial of either topical fluorouracil or topical imiquimod. Coverage may be denied if the required prerequisite therapy is not documented.

    • Required prerequisite: trial of either topical fluorouracil or topical imiquimod.
    • Document the prior topical therapy in the request.
    Step Therapy

    Generic Dapagliflozin Trial Required

    Before approval of Farxiga, document a trial of generic dapagliflozin. Failure to meet this step-therapy requirement may result in nonapproval.

    • Required prerequisite: trial of generic dapagliflozin.
    • Document the generic trial and its outcome.
    Step Therapy

    Generic Zonisamide Trial Required for New Starts

    Initial Therapy Criteria

    Prerequisite topical therapy

    Initial coverage of diclofenac sodium gel 3% requires a trial of either topical fluorouracil or topical imiquimod.

    Required prerequisite therapy

    • Topical fluorouracil: Trial of topical fluorouracil
    • Topical imiquimod: Trial of topical imiquimod

    Farxiga initial therapy

    Criteria: 1

    Generic prerequisite: Trial of generic dapagliflozin

    Continuation Therapy Criteria

    Zonisade continuation

    Continuation of prior therapy may be approved.

    Continuation: Member is continuing prior Zonisade therapy

    The step requirement applies to new starts only.

    Step Therapy Requirements

    StepRequired therapyTarget medicationApplicability
    1
    Trial of either topical fluorouracil or topical imiquimod
    Diclofenac sodium gel 3%
    Initial coverage
    StepRequired therapyTarget medicationApplicability
    1
    Trial of generic dapagliflozin
    Farxiga
    Before approval
    StepRequired therapyTarget medicationApplicability
    1
    Trial of generic zonisamide capsule
    Zonisade
    New starts only; continuation of prior therapy may be approved
    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyACTINIC KERATOSIS - SCORE
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 202744d
    Next Review DateN/A
    Key ActionDocument a trial of either topical fluorouracil or topical imiquimod before requesting diclofenac sodium gel 3% coverage.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and DocumentationInitial Therapy CriteriaContinuation Therapy CriteriaStep Therapy Requirements

    For new starts, Zonisade coverage requires a trial of generic zonisamide capsules. Continuation of previously approved therapy may be approved without applying the new-start step.

    • New starts: document a trial of generic zonisamide capsules.
    • Continuation of prior therapy may be approved.

    Zonisade initial therapy

    Criteria: 1

    Generic prerequisite: Trial of generic zonisamide capsule

    Step applies to new starts only.